Evidence suggests that combining metformin with standard of care could increase survival and offer other benefits to patients with high-volume disease.

Panelist discusses how the second interim overall survival data from MARIPOSA-2, presented at the European Society for ...

The latest edition of EMJ Oncology is out now, featuring coverage from the 2024 European Society for Medical Oncology ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious ...

Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...

The congress is a collaboration of the European Society for Medical Oncology (ESMO), the European SocieTy for Radiotherapy ...

Abstracts will be made available on the ESMO I-O website on 5 December 2024 at 00:05 CET. The poster containing new data, not in the abstract, will be available on the Posters & Publications section ...

Panelist discusses how an early analysis of the mechanisms of acquired resistance to first-line treatment with amivantamab ...

This Industry Satellite Symposium was presented at the European Society for Medical Oncology (ESMO) Congress 2024, held in ...

Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from the sovleplenib ESLIM-01 Phase III trial, as well as several investigator-initiated studies of compounds ...

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / October 28, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global ...

A nurse practitioner discusses ASCO’s recommendations of CDK4/6 inhibitors—namely abemaciclib and ribociclib—in certain high-risk breast cancer settings.